Edition:
United Kingdom

Nabriva Therapeutics PLC (NBRV.OQ)

NBRV.OQ on NASDAQ Stock Exchange Global Select Market

2.53USD
21 Sep 2018
Change (% chg)

$-0.01 (-0.39%)
Prev Close
$2.54
Open
$2.57
Day's High
$2.57
Day's Low
$2.53
Volume
72,593
Avg. Vol
117,589
52-wk High
$8.56
52-wk Low
$2.34

Chart for

About

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel... (more)

Overall

Beta: --
Market Cap(Mil.): $304.02
Shares Outstanding(Mil.): 36.63
Dividend: --
Yield (%): --

Financials

  NBRV.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -24.70 -- --
ROI: -87.80 1.79 14.61
ROE: -88.10 3.28 16.33

Nabriva shares tumble as safety worries plague pneumonia drug

Nabriva Therapeutics Plc's antibiotic drug to treat a common form of pneumonia met the main goal of a key clinical trial, but concerns over its side effects sent the drug developer's shares down 13 percent on Monday.

21 May 2018

UPDATE 3-Nabriva shares tumble as safety worries plague pneumonia drug

* Co to seek approval for drug in Q4 2018 (Adds analyst quote, updates stock price)

21 May 2018

Nabriva's pneumonia drug succeeds in late-stage study

May 21 Nabriva Therapeutics Plc said on Monday its drug to treat adults suffering from a type of pneumonia met the main goal of a late-stage study.

21 May 2018

BRIEF-Nabriva Therapeutics Reports Q1 Loss Per Share $0.36

* NABRIVA THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS

08 May 2018

BRIEF-Nabriva Therapeutics And Roivant Sciences Enter Into License Agreement

* NABRIVA THERAPEUTICS AND ROIVANT SCIENCES ENTER INTO LICENSE AGREEMENT TO DEVELOP AND COMMERCIALIZE LEFAMULIN IN GREATER CHINA

27 Mar 2018

Earnings vs. Estimates